Side effects Diclofenac

1 side effects

1.1 cardiac
1.2 gastrointestinal
1.3 hepatic
1.4 renal
1.5 mental health

side effects

diclofenac consumption has been associated increased vascular , coronary risk in study including coxib, diclofenac, ibuprofen , naproxen. upper gastrointestinal complications reported. major vascular events increased third diclofenac, chiefly due increase in major coronary events. compared placebo, of 1000 patients allocated diclofenac year, 3 more had major vascular events, 1 of fatal. vascular death increased diclofenac.

cardiac

in 2013, study funded core grants uk medical research council , british heart foundations, , collaboration coordinated clinical trial service unit & epidemiological studies unit (ctsu) @ university of oxford, uk; major vascular events increased third diclofenac (rate ratio 1·41,95% ci 1·12–1·78; p=0·0036), chiefly due increase in major coronary events (1·70, 1·19–2·41; p=0·0032). compared placebo, of 1000 patients allocated diclofenac year, 3 more had major vascular events, 1 of fatal. vascular death increased diclofenac (1·65, 0·95–2·85, p=0·0187).

following identification of increased risks of heart attacks selective cox-2 inhibitor rofecoxib in 2004, attention has focused on other members of nsaids group, including diclofenac. research results mixed, meta-analysis of papers , reports april 2006 suggesting relative increased rate of heart disease of 1.63 compared nonusers. professor peter weissberg, medical director of british heart foundation said, however, increased risk small, , many patients chronic debilitating pain may feel small risk worth taking relieve symptoms . aspirin found not increase risk of heart disease; however, known have higher rate of gastric ulceration diclofenac.

a subsequent large study of 74,838 users of nsaids or coxibs found no additional cardiovascular risk diclofenac use. large study of 1,028,437 danish users of various nsaids or coxibs found use of nonselective nsaid diclofenac , selective cyclooxygenase-2 inhibitor rofecoxib associated increased risk of cardiovascular death (odds ratio, 1.91; 95% confidence interval, 1.62 2.42; , odds ratio, 1.66; 95% confidence interval, 1.06 2.59, respectively), dose-dependent increase in risk. in britain medicines , healthcare products regulatory agency (mhra) said in june 2013 drug should not used people serious underlying heart conditions—people had suffered heart failure, heart disease or stroke advised stop using completely. of january 15, 2015 mhra announced diclofenac reclassified prescription-only medicine (pom) due risk of cardiovascular adverse events.

diclofenac similar in cox-2 selectivity celecoxib. review fda medical officer david graham concluded diclofenac increase risk of myocardial infarction.

gastrointestinal

gastrointestinal complaints noted. development of ulceration and/or bleeding requires immediate termination of treatment diclofenac. patients receive gastro-protective drug prophylaxis during long-term treatment (misoprostol, ranitidine 150 mg @ bedtime or omeprazole 20 mg @ bedtime).

hepatic

liver damage occurs infrequently, , reversible. hepatitis may occur without warning symptoms , may fatal. patients osteoarthritis more develop symptomatic liver disease patients rheumatoid arthritis. liver function should monitored regularly during long-term treatment. if used short-term treatment of pain or fever, diclofenac has not been found more hepatotoxic other nsaids.
as of december 2009, endo, novartis, , fda notified healthcare professionals add new warnings , precautions potential elevation in liver function tests during treatment products containing diclofenac sodium.
cases of drug-induced hepatotoxicity have been reported in first month, can occur @ time during treatment diclofenac. postmarketing surveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant hepatitis , without jaundice, , liver failure. of these reported cases resulted in fatalities or liver transplantation.
physicians should measure transaminases periodically in patients receiving long-term therapy diclofenac. based on clinical trial data , postmarketing experiences, transaminases should monitored within 4 8 week after initiating treatment diclofenac.

renal

nsaids associated adverse renal [kidney] effects caused reduction in synthesis of renal prostaglandins in sensitive persons or animal species, , potentially during long-term use in nonsensitive persons if resistance side effects decreases age. however, side effect cannot avoided merely using cox-2 selective inhibitor because, both isoforms of cox, cox-1 , cox-2, expressed in kidney... consequently, same precautions regarding renal risk followed nonselective nsaids should used when selective cox-2 inhibitors administered. however, diclofenac appears have different mechanism of renal toxicity.
studies in pakistan showed diclofenac caused acute kidney failure in vultures when ate carcasses of animals had been treated it. drug-sensitive species , individual humans assumed lack genes expressing specific drug detoxification enzymes.

mental health

mental health side effects have been reported. these symptoms rare, exist in significant enough numbers include potential side effects. these include depression, anxiety, irritability, nightmares, , psychotic reactions.




^ bhala, n.; emberson, j.; et al. (2013). vascular , upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data randomised trials . lancet. 382 (9894): 769–779. doi:10.1016/s0140-6736(13)60900-9. pmc 3778977 . pmid 23726390. 
^ kearney pm, baigent c, godwin j, halls h, emberson jr, patrono c (2006). selective cyclo-oxygenase-2 inhibitors , traditional non-steroidal anti-inflammatory drugs increase risk of atherothrombosis? meta-analysis of randomised trials . bmj. 332 (7553): 1302–8. doi:10.1136/bmj.332.7553.1302. pmc 1473048 . pmid 16740558. cs1 maint: uses authors parameter (link)
^ solomon dh, avorn j, stürmer t, glynn rj, mogun h, schneeweiss s (2006). cardiovascular outcomes in new users of coxibs , nonsteroidal antiinflammatory drugs: high-risk subgroups , time course of risk . arthritis rheum. 54 (5): 1378–89. doi:10.1002/art.21887. pmid 16645966. cs1 maint: uses authors parameter (link)
^ fosbøl el, folke f, jacobsen s, rasmussen jn, sørensen r, schramm tk, andersen ss, rasmussen s, poulsen he, køber l, torp-pedersen c, gislason gh (2010). cause-specific cardiovascular risk associated nonsteroidal antiinflammatory drugs among healthy individuals . circ cardiovasc qual outcomes. 3 (4): 395–405. doi:10.1161/circoutcomes.109.861104. pmid 20530789. cs1 maint: uses authors parameter (link)
^ heart risk warning on painkiller . 29 june 2013 – via www.bbc.co.uk. 
^ press release: diclofenac tablets available prescription medicine . medicines , healthcare products regulatory agency. january 14, 2015. retrieved january 14, 2015. 
^ fitzgerald ga, patrono c (2001). coxibs, selective inhibitors of cyclooxygenase-2 . n engl j med. 345 (6): 433–42. doi:10.1056/nejm200108093450607. pmid 11496855. cs1 maint: uses authors parameter (link)
^ graham dj (2006). cox-2 inhibitors, other nsaids, , cardiovascular risk: seduction of common sense . jama. 296 (13): 1653–6. doi:10.1001/jama.296.13.jed60058. pmid 16968830. cs1 maint: uses authors parameter (link)
^ fda.gov . 
^ brater dc (2002). renal effects of cyclooxygyenase-2-selective inhibitors . j pain symptom manage. 23 (4 suppl): s15–20; discussion s21–3. doi:10.1016/s0885-3924(02)00370-6. pmid 11992745. cs1 maint: uses authors parameter (link)
^ becker, rachel. cattle drug threatens thousands of vultures . nature. doi:10.1038/nature.2016.19839. 
^ diclofenac side effects . drugs.com. retrieved 21 january 2013.